Hofer A, Rettenbacher M A, Edlinger M, Kemmler G, Widschwendter C G, Fleischhacker W W
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria.
Acta Psychiatr Scand. 2007 Nov;116(5):354-61. doi: 10.1111/j.1600-0447.2007.01087.x. Epub 2007 Sep 14.
In this prospective study, patients with schizophrenia were followed up for 3 months to investigate the impact of sociodemographic factors, psychopathology, change in psychopathology and side effects on subjective response and attitudes toward antipsychotics during the initial treatment period.
We investigated 42 patients starting treatment with a new-generation antipsychotic. Next to the registration of demographic data various rating scales were used: the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and the Drug Attitude Inventory (DAI).
Two patients experienced a first episode of the illness and were neuroleptic naïve, and 40 had suffered from at least one prior episode of schizophrenia. Longer duration of illness as well as the amelioration of psychopathological symptoms had a positive impact on subjective response to treatment. Correlations between antipsychotic-induced side effects and drug attitude tended to be weak.
Our results emphasize the necessity of improving psychopathological symptoms during the initial treatment period to improve attitudes toward and compliance with treatment.
在这项前瞻性研究中，对精神分裂症患者进行了3个月的随访，以调查社会人口学因素、精神病理学、精神病理学变化和副作用对初始治疗期间主观反应及对抗精神病药物态度的影响。
我们对42例开始使用新一代抗精神病药物治疗的患者进行了调查。除了记录人口统计学数据外，还使用了各种评定量表：阳性和阴性症状量表（PANSS）、临床研究评定量表（UKU）副作用评定量表和药物态度量表（DAI）。
2例患者为首次发病且未使用过抗精神病药物，40例患者至少有过一次精神分裂症发作史。病程较长以及精神病理症状的改善对治疗的主观反应有积极影响。抗精神病药物引起的副作用与药物态度之间的相关性往往较弱。
我们的结果强调了在初始治疗期间改善精神病理症状以改善对治疗的态度和依从性的必要性。
